From: Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
Variable | PFS (OR, 95% CI) | OS (OR, 95% CI) | ||
---|---|---|---|---|
MDACC | JICR | MDACC | JICR | |
FIGO stage | ||||
 I | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 II | 1.07 (0.35–3.14) | 1.22 (0.54–4.19) | 1.24 (0.40–3.98) | 1.53 (0.63–4.24) |
 III | 1.83 (1.18–4.29) | 3.24 (1.61–8.93) | 2.28 (1.14–8.65) | 3.56 (2.02–8.27) |
 IV | 2.26 (1.24–5.25) | 4.37 (2.52–11.05) | 3.77 (2.08–10.24) | 5.13 (2.72–12.27) |
Ascites | ||||
 No | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 Yes | 1.40 (1.16–2.03) | 1.85 (1.47–2.73) | 1.73 (1.26–2.49) | 2.01 (1.55–2.47) |
Residual tumors | ||||
 No | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 Yes | 8.54 (4.24–16.82) | 9.12 (4.50–17.87) | 6.24 (3.19–16.39) | 7.35 (3.72–14.08) |
Neo-chemotherapy | ||||
 Yes | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 No | 1.28 (0.88–2.24) | 1.27 (1.19–1.42) | 1.26 (0.36–6.22) | 1.17 (0.75–1.93) |
Chemotherapy, including paclitaxel | ||||
 Yes | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 No | 1.00 (0.61–2.62) | 1.07 (0.86–1.40) | 1.21 (0.38–4.77) | 1.13(0.74–1.86) |
CA-125, decreasing kinetics | ||||
 ≥1/32 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 <1/32 | 1.06 (0.84–1.83) | 1.37 (1.14–1.92) | 1.10 (0.56–2.84) | 1.02 (0.65–2.85) |
Baseline CA-125 | 1.00 (0.98–1.02) | 1.00 (0.98–1.02) | 1.00 (0.97–1.03) | 1.00 (0.97–1.03) |
CA-125 level at relapse | 1.00 (0.97–1.04) | 1.00 (0.98–1.01) | 1.01 (0.98–1.02) | 1.01 (0.99–1.02) |
Nadir CA-125 | 1.02 (1.00–1.04) | 1.02 (1.00–1.03) | 1.03 (1.01–1.06) | 1.03 (1.00–1.05) |